A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT04600778 | Unknown Phase 2 FDA Drug

• 1 other identifier: LVC-N91115-PS-II-01
• Study Type: interventional
• Target: 108
• Locations: 0 countries
• Sites: N/A

Brief Summary

Brief Summary: The purpose of this study is to to evaluate the efficacy and safety of Cavosonstat administered twice daily compared with Placebo for 24 Weeks in adult subjects with Chronic Obstructive Pulmonary Disease (COPD) Detailed Description:To investigate the effect of cavosonstat compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over 24 weeks of treatment. To investigate:

1. 1.The effect of cavosonstat compared with placebo, on the duration from baseline to first moderate AECOPD event
2. 2.The effect of cavosonstat compared with placebo, on respiratory function, as assessed by post-bronchodilator percent-predicted forced expiratory volume in one second (ppFEV1)
3. 3.The effect of cavosonstat compared with placebo on annualized rate of moderate AECOPD over 24 weeks of treatment
4. 4.The effect of cavosonstat compared with placebo on annualized rate of severe AECOPD over 24 weeks of treatment
5. 5.The safety and tolerability of cavosonstat compared with placebo
6. 6.The pharmacokinetics of cavosonstat
7. 7.Assessment of quality of life

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Outcome Measures

Primary Outcomes (1)

• Annualized rate of moderate-to-severe acute exacerbations of COPD

  To investigate the effect of cavosonstat compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over 24 weeks of treatment.

  24 weeks

Study Arms (4)

placebo

PLACEBO COMPARATOR

twice daily

Other: placebo

Cavosonstat 5 mg

EXPERIMENTAL

twice daily

Drug: Cavosonstat 5 mg

Cavosonstat 10 mg

EXPERIMENTAL

twice daily

Drug: Cavosonstat 10 mg

Cavosonstat 25 mg

EXPERIMENTAL

twice daily

Drug: Cavosonstat 25 mg

Interventions

placebo OTHER

placebo

placebo

Cavosonstat 5 mg DRUG

Cavosonstat (low dose)

Cavosonstat 5 mg

Cavosonstat 10 mg DRUG

Cavosonstat (medium dose)

Cavosonstat 10 mg

Cavosonstat 25 mg DRUG

Cavosonstat (high dose)

Cavosonstat 25 mg

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with moderate to severe COPD, who meet the following criteria (full details in main text):
• Male or female aged between 40 and 75 years inclusive, at the time of informed consent
• Patients with symptomatic COPD as defined by the 2019 GOLD diagnostic criteria
• Post-bronchodilator (four puffs of albuterol) spirometry at screening demonstrating the following:
• FEV1/forced vital capacity (FVC) ratio of \<0.70
• FEV1 ≥30% and FEV1 \<80% of predicted normal
• Current or prior history of ≥10 pack-years of cigarette smoking
• Participants with COPD Assessment Test (CAT) score ≥10 at screening
• Participants with a documented history of ≥1 moderate exacerbation within the year prior to screening
• Participants with standard of care background therapy for three months and at a stable dose for at least one month, including either:
• Single therapy: long-acting muscarinic agonist (LAMA), or
• Double therapy: long-acting beta agonist (LABA) plus long-acting muscarinic agonist (LAMA) or inhaled corticosteroid (ICS) plus LABA or ICS plus LAMA, or
• Triple therapy: LABA plus LAMA plus ICS
• Meet the concomitant medication restrictions and continue to do so throughout the study
• Have body mass index \>21 kg/m2 and \< 35 kg/m2

You may not qualify if:

• Patients meeting any of the following criteria must be excluded from the study (full details in main text):
• Patients with other respiratory disorders: current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, uncontrolled or unstable sleep apnea, cor pulmonale, clinically significant pulmonary hypertension or other active pulmonary diseases
• Chest X-ray (or computerized tomography \[CT\] scan) reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD
• Moderate or severe AECOPD within the previous four weeks
• An upper or lower respiratory tract infection that required the use of antibiotics within the previous four weeks
• Long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for more than 12 hours a day
• Oral therapies for COPD (e.g. oral steroids, theophylline and roflumilast) or antibiotics or oral corticosteroid therapy within four weeks prior to screening
• Prior history of, or planned pneumonectomy or lung volume reduction surgery
• Participation in the acute phase of a pulmonary rehabilitation program within four weeks of screening or planned during the study
• History of malignancy of any organ system within five years, except skin cancer which has been stable over one year and the investigator believes is no clinical significance.
• Patients with uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the Investigator believes are clinically significant. This includes any hepatic disease or moderate to severe renal impairment.
• Documented clinically significant cardiovascular disease such as: any history of arrhythmias, angina, recent (\<1 year) or suspected myocardial infarction, congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of hypertension within 3 months prior to Screening.
• Known or suspected history of alcohol or drug abuse within the last 5 years. Positive urine drug screen and blood alcohol level screen.
• Clinically significant abnormal values for laboratory safety tests (hematology, blood chemistry, viral serology or urinalysis) at Screening, as determined by the Investigator.
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than twice the upper limit of normal.

Sponsors & Collaborators

• GSNOR Therapeutics, Inc.: lead

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

cavosonstat

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 19, 2020
• First Posted: October 23, 2020
• Study Start: February 3, 2021
• Primary Completion: December 31, 2021
• Study Completion: April 30, 2022
• Last Updated: October 23, 2020

Record last verified: 2020-10